Forest Ray

A quantitative continuous score identified patients with a TROP2 biomarker likely to respond to the antibody-drug conjugate, a study presented at WCLC showed. 

Patients will be offered germline genetic testing after an assessment that includes genetic, lifestyle, and other clinical risk factor analysis.

The biomarker p-tau 217 best correlated with other established signs of Alzheimer's disease in a head-to-head study evaluating six blood-based assays.

The UK startup hopes to quickly select a lead ASO therapy to advance to clinical studies for a rare brain disorder next year, as it eyes the UK and US markets.

Project Africa GRADIENT aims to gather and analyze pharmacogenetic data specific to African populations with funding from Novartis and GlaxoSmithKline.

The Australian firm seeks to validate its DiGAP platform in a clinical study by categorizing ALS patients according to their most affected biological pathways.

The Dutch company is developing a pipeline of vectorized antibodies to clear pathological protein aggregates from affected cells in neurodegenerative disorders.

The company recently used its blood-based LuGene test to identify eight lupus molecular subtypes that may be used to predict flare-ups and therapy response.

Despite some CMS policies designed to improve patient access to cell and gene therapies, the reliance on a value-based pricing model drew sharp criticism in an ASGCT session.

At the meeting, companies and academic centers presented early and long-term follow-up data on investigational cell therapies in several tumor types.